Trial Outcomes & Findings for Investigation of a New Rectal Catheter for Users of Transanal Irrigation (NCT NCT06389396)

NCT ID: NCT06389396

Last Updated: 2025-06-12

Results Overview

After visit 1 and visit 2, the primary endpoint, defined as if it was possible to perform transanal irrigation, was answered by a yes/no answer.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

20 participants

Primary outcome timeframe

Evaluated at Visit 1 and Visit 2 (within a time duration of up to 17 days)

Results posted on

2025-06-12

Participant Flow

Between April 2024 and July 2024, 20 users were recruited for the study from two sites and encompassed the Intention to treat (ITT) population.

The 20 recruited participants were randomized into the two intervention arms. No participants were excluded or discontinued. No adverse events were reported.

Participant milestones

Participant milestones
Measure
Investigational Device Then Comparator Device
Participants were randomly assigned to the sequence of two intervention arms, in block sizes of 4. At the first intervention the transanal irrigation (TAI) procedure was performed with the CP362 Test Catheter together with the CE-marked Peristeen® Plus TAI system, then, at the second intervention the TAI procedure was performed with the Comparator catheter, the Peristeen® Plus rectal balloon catheter, together with the CE-marked Peristeen® Plus TAI system.
Comparator Device Then Investigational Device
Participants were randomly assigned to the sequence of two intervention arms, in block sizes of 4. At the first intervention the transanal irrigation (TAI) procedure was performed with the Comparator catheter, the Peristeen® Plus rectal balloon catheter, together with the CE-marked Peristeen® Plus TAI system, then, at the second intervention the TAI procedure was performed with CP362 Test Catheter together with the CE-marked Peristeen® Plus TAI system
Visit 1
STARTED
10
10
Visit 1
COMPLETED
10
10
Visit 1
NOT COMPLETED
0
0
Visit 2
STARTED
10
10
Visit 2
COMPLETED
10
10
Visit 2
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Total ITT Population
n=20 Participants
Each investigation arm consisted of two test visits. On each visit, the participants underwent one TAI procedure with either the CP362 test catheter or the Comparator catheter, according to the randomization scheme.
Age, Continuous
61 years
STANDARD_DEVIATION 11.3 • n=20 Participants
Sex: Female, Male
Female
15 Participants
n=20 Participants
Sex: Female, Male
Male
5 Participants
n=20 Participants
Region of Enrollment
Denmark
20 participants
n=20 Participants

PRIMARY outcome

Timeframe: Evaluated at Visit 1 and Visit 2 (within a time duration of up to 17 days)

Population: The full analysis set

After visit 1 and visit 2, the primary endpoint, defined as if it was possible to perform transanal irrigation, was answered by a yes/no answer.

Outcome measures

Outcome measures
Measure
Investigational Device - Newly Developed TAI Catheter.
n=20 Participants
The CP362 Test Catheter, the investigational device, was used to perform TAI procedures together with the CE-marked Peristeen® Plus TAI system.
Comparator Device - Peristeen Plus
n=20 Participants
Comparator catheter. The Peristeen® Plus rectal balloon catheter, was used together with the CE-marked Peristeen® Plus TAI system.
Was it Possible to Perform Transanal Irrigation?
20 Number of participants who replied YES
20 Number of participants who replied YES

Adverse Events

Investigational Device - Newly Developed TAI Catheter.

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Comparator Catheter - Peristeen Plus

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Julie Schnipper, Medical Writer

Coloplast A/S

Phone: 004549111257

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place